Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2005-06-28
2005-06-28
Wax, Robert A. (Department: 1653)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C530S317000, C540S455000, C514S183000
Reexamination Certificate
active
06911428
ABSTRACT:
The present invention is directed to certain diaryl amide compounds as NS3-Serine protease inhibitors of hepatitis C virus. A particularly preferred compound is of the formula:
REFERENCES:
patent: 5712145 (1998-01-01), Houghton et al.
patent: 381 216 (1990-08-01), None
patent: WO 89/04669 (1989-06-01), None
patent: WO 98/07734 (1998-02-01), None
patent: WO 98/17679 (1998-04-01), None
patent: WO 98/22496 (1998-05-01), None
patent: WO 00/09543 (2000-02-01), None
patent: WO 00/09558 (2000-02-01), None
Llinas-Brunet et al.: “Studies on the C-Terminal of Hexapeptide Inhibitors of the Hepatitis C Virus Serine Protease”Bioorganic&Medicinal Chemistry Letters, Oxford, GB, 8(19):2719-2724 (1998).
Pizzi, (1994)Proc. Natl. Acad. Sci.(USA) 91:888-892.
Failla (1996)folding&Design1:35-42.
Kollykhalov (1994)J. Virol.68:7525-7533.
Komoda (1994)J. Virol68:7351-7357.
Landro (1997)Biochem36:9340-9348.
Ingallinella (1998)Biochem37:8906-8914.
Llinas-Brunet (1998)Bioorg. Med. Chem. Lett, 8:1713-1718.
Martin (1998)Biochem37:11459-11468.
Dimasi (1997)J. Virol.71:7461-7469.
Martin (1997)Protein Eng.10:607-614.
Elzouki (1997)J. Hepat.27:42-48.
Bio World Today9(217): 4 (Nov. 10, 1998).
Berenguer (1998)Proc. Assoc. Am. Physicians110(2): 98-112.
Hoofnagle (1997)New England Journal Med.336:347.
Zhang (199)Analytical Biochemistry270:268-275.
Sali (1998)Biochemistry3392-3401.
Barlos (1991)Int. J. Pept. Protein Res513-520.
Holmberg (1979)Acta Chem. Scand.B33:410-412.
Agrawal(1999)HepatologySupplement to vol. 30 “Development and Characterization of Hepatitis C Virus Serine Protease Cell-based Trans-Cleavage Assay”.
Hughes (1992)Org. Reactions42:335.
Heck (1989)Org. Reactions27:345-390.
Han, (2000)Bioorganic&Medicinal Chemistry Letters 10 “α-Ketoamides, α-Ketoesters and α-Kiketones as HCV NS3 Protease Inhibitors”pp. 711-713.
Marchetti(1999)Synlett, vol. S1, “Synthesis of Two Novel Cyclic Biphenyl Ether Analogs of an Inhibitor of HCV NS3 Protease”, pp 1000-1002.
Arasappan Ashok
Chen Kevin X.
Girijavallabhan Viyyoor M.
Lovey Raymond G.
Malcolm Bruce A.
Kalyanaraman Palaiyur S.
Mondesi Robert B.
Schering Corporation
Wax Robert A.
LandOfFree
Diaryl peptides as NS3-serine protease inhibitors of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Diaryl peptides as NS3-serine protease inhibitors of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Diaryl peptides as NS3-serine protease inhibitors of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3499485